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ABSTRACT
Introduction: People with bronchiectasis frequently request specialist advice to prepare for travelling, but
there are few publications providing advice on safe travel with bronchiectasis. There is a need for
recommendations on adapting everyday treatment to the requirements during travelling.
Methods: A panel of 13 patient volunteers formulated questions regarding different aspects of travelling,
including safety of travel, maintaining regular treatment during travel, and dealing with deterioration while
away. Patient input was used to derive a questionnaire and circulated among a panel of bronchiectasis
experts. Where 80% or more experts agreed on a response, a recommendation was made.
Results: A total of 26 bronchiectasis experts answered the questionnaire. Recommendations were made on
safety of travel, choice of destinations and activities, choice of travel insurance, carrying medications and
devices, maintaining regular treatments in transport, documentation to be provided and oxygen
requirements. Some statements did not reach an 80% agreement; in many cases these statements may be
valid for some, but not all bronchiectasis patients.
Conclusions: The general agreement was that it is considered safe for most people with bronchiectasis to
travel. Careful planning and preparation with robust communication between patients and their healthcare
provider prior to travel for different scenarios is fundamental to a successful journey.
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It is safe for most people with bronchiectasis to travel. Careful planning and preparation for
different scenarios are fundamental to a successful journey. http://bit.ly/2yWEowA
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ORIGINAL ARTICLE
BRONCHIECTASIS
Introduction
With increasing availability of transportation, many people of older age and with chronic health
conditions are travelling for work or leisure. Bronchiectasis is a chronic condition punctuated by episodes
of exacerbations, and treated regularly with oral and inhaled medications and airway clearance [1, 2]. The
requirement for uninterrupted treatment to maintain lung health, the risk of a pulmonary exacerbation,
and presence of daily symptoms may all interfere with travel. However, maintaining an active life including
travel is important for people with bronchiectasis in order to keep working, maintain family and social
relationships, and otherwise enjoy what life has to offer. People with bronchiectasis frequently seek advice
from healthcare providers before travel regarding safety of travelling, maintenance of a treatment routine
while travelling, providing documentation for airline companies and insurance, security screening,
obtaining permission for extra hand luggage when flying, and planning to engage in recreational activities.
EMBARC, the European Multicenter Bronchiectasis Audit and Research Collaboration, is an ERS clinical
research collaboration dedicated to advancing research and care of patients with bronchiectasis [3]. One of
the aspects of this collaboration involves working with patient volunteers, coordinated by the European
Lung Foundation (ELF) to involve people with bronchiectasis in research and promotion of care [4]. Some
aspects of this collaboration resulted in patient and caregiver-focused documents [5].
Finding recommendations to prepare people with bronchiectasis for travel was an initiative of individuals
who are part of the ELF bronchiectasis patient advisory group (PAG). International guidelines on
bronchiectasis care do not refer to care while travelling; recommendations for travelling for people with
cystic fibrosis (CF) [6] may not always apply for bronchiectasis, as typically people with bronchiectasis are
older and suffer from more prevalent comorbidities than people with CF, and that treatment
recommendations in general, including access to drugs and devices, are different between CF and
bronchiectasis.
Methods
Creating a set of recommendations for travel was one of the EMBARC–ELF PAG initiatives. A group of 13
people with bronchiectasis, volunteering as part of the ELF bronchiectasis PAG, together with three
bronchiectasis experts (PG, MS and JDC) developed a list of questions that patients may have regarding
various aspects of travelling. The questions were circulated among a wider (45 members) PAG and revised
according to further recommendations and comments. A questionnaire was then formed incorporating all
questions (table 1; similar items were unified into one question) with suggested responses based on the
literature and common practice. The questionnaire was then turned into an online survey. An invitation to
participate, along with previous similar documents [6–8] were sent to 37 bronchiectasis experts that were
globally based and affiliated to EMBARC. The questionnaire contained 10 questions with a total of 41
statements. Experts were asked for an “agree/disagree” response and free-text comments were encouraged
for each statement. Responses were recorded and recommendations made where a statement reached 80%
agreement or higher.
In addition, a systematic PubMed search was conducted for the terms: “bronchiectasis”; “non cystic
fibrosis bronchiectasis”; “travel”; “high altitude”; supplemental oxygen”; “SCUBA diving”; “cross infection”,
and also “cystic fibrosis” and “travel” to identify any previous publications on travelling with
bronchiectasis.
Results
No studies were identified that assessed the safety of travel, including air travel, in people with
bronchiectasis. Consensus statements regarding travel in people with CF [6] and air travel in chronic
obstructive pulmonary disease (COPD) [9] exist but do not make specific recommendations for people
with bronchiectasis without CF or COPD, respectively. Documents regarding air travel [10] and SCUBA
diving [11] make references to bronchiectasis.
A total of 26 respondents based at institutions in Europe (n=19), United States (n=3), Australia and New
Zealand (n=2), India (n=1), and Israel (n=1) completed an online survey. The questions and percentage of
responders that agreed are listed in table 1.
Is it safe for all people with bronchiectasis to travel?
Recommendations:
1) Most people with bronchiectasis can safely travel for vacation or business (96% agreement).
2) It is best to avoid travelling during periods of unstable disease, such as during exacerbations (92%
agreement).
3) People with bronchiectasis should consult their healthcare providers and plan for travel (85%
agreement).
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TABLE 1 Statements included in the questionnaire for experts and percentage agreement
Statement Agree Disagree
Is it safe for all people with bronchiectasis to travel?
Most people with bronchiectasis can safely travel for vacation or business 96% 4%
It is best to avoid travelling during periods of unstable disease, such as during exacerbations 92% 8%
People with bronchiectasis should consult their healthcare providers and plan for travel 85% 15%
People with very severe bronchiectasis (e.g. candidate for lung transplantation, frequent hospitalisation) should be
advised not to travel abroad
73% 27%
Planning travel: are there destinations and conditions that certain people with bronchiectasis should avoid?
People with bronchiectasis should try to avoid travelling to places with high levels of air pollution 73% 27%
People with bronchiectasis should try to avoid travelling to places with a high prevalence of NTM (e.g. Hawaii, USA) 38% 62%
People with bronchiectasis should try to avoid travelling during influenza season 35% 65%
People with bronchiectasis should consult their healthcare professional regarding staying at high altitudes 85% 15%
Travelling to high-altitude destinations (above 3050 m/10000 ft) should be avoided in people with bronchiectasis# 32% 68%
People with bronchiectasis should preferably travel to destinations with a nearby bronchiectasis centre 31% 69%
What travel insurance should people with bronchiectasis acquire?
Health insurance with coverage of deterioration of a chronic condition 100%
Health insurance with coverage of hospital admission and emergency room visits# 100%
Health insurance with coverage of repatriation# 68% 32%
What medications and devices should people with bronchiectasis carry with them when travelling?
When travelling, it is recommended that people with bronchiectasis should continue taking their regular
treatments and make arrangements to take enough medications and equipment for the duration of their travel
100%
When travelling, people with bronchiectasis should consult their healthcare professional or respiratory
physiotherapist regarding possible alternatives to heavy or large equipment (e.g. nebulisers)
100%
People with bronchiectasis who suffer frequent pulmonary exacerbations should consult their specialist regarding
carrying antibiotics to be used in case of a pulmonary exacerbation when travelling
100%
Medications taken for travel should be properly stored according to manufacturer’s recommendations (particularly
storage temperature, light exposure)
100%
Electricity requirements (e.g. for a nebuliser) and cleaning instructions should be known prior to travelling and
proper adaptations, including checking batteries, should be planned
100%
How can people with bronchiectasis maintain regular treatments when in transport?
It is advised that airway clearance and inhalations are performed while waiting at airports before and after flights.
This is best planned ahead and checked with the airport for the best place to do this
77% 23%
While it is not advised to take cough suppressants for bronchiectasis, it may be considered for long flights where
a cough may be disturbing to other passengers
35% 65%
Do people with bronchiectasis need to prepare and carry certain documents?
It is advised that patients with bronchiectasis carry documentation from the last clinic/hospitalisation visit,
translated into English and preferably also into the language of the country of destination
81% 19%
A document for travel may be prepared and should include: patient’s health status, allergies, chronic bacterial
infections, regular medications and devices used regularly, recommended medications during exacerbation
100%
It is advised that patients with bronchiectasis carry a translation of a disability card# (such as a European Union
disability parking card) if eligible and where available
84% 16%
When travelling in a guided tour, it is advised that people with bronchiectasis should notify the travel company of
their condition
69% 31%
What are oxygen requirements on the flight and at the travel destination?
Oxygen requirements during commercial flights should be predicted before flight 100%
In people with an FEV1 <55% pred or oxygen saturation <93% at ambient air, a hypoxia inhalation test should be
performed
77% 23%
In people with FEV1 <1.5 L, a hypoxia inhalation test should be performed
# 44% 56%
When planning travel to destinations between 2000 and 3050 m, considerations as for commercial flights should
be made
92% 8%
How else can people with bronchiectasis be prepared to travel?
It is recommended that people with bronchiectasis seek advice for travellers and follow recommended
immunisations for the destination
100%
Recommended medications while travelling (such as for the prevention of malaria) should be checked for
interactions with regular treatments and with treatments during exacerbations
100%
It is recommended that people with bronchiectasis should be stable prior to travelling, if symptoms typical for an
exacerbation develop shortly before travelling, treatment should be started and travel postponed if possible
96% 4%
People with severe bronchiectasis and chronic Pseudomonas sp. infection may be advised to receive treatment
with an intravenous antibiotic course shortly before travelling to prevent an exacerbation while away
50% 50%
Continued
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Other statement considered:
• People with very severe bronchiectasis (e.g. candidates for lung transplantation and with frequent
hospitalisations) should be advised not to travel abroad (73% agreement).
There is scarce evidence regarding safety of travel in people with bronchiectasis, and these
recommendations are mostly based on a common-sense approach considering the nature of bronchiectasis.
Most people with bronchiectasis should have no limitations and often do not seek expert advice before
travelling. In other cases, an individual approach should be made, taking into consideration the severity of
the condition, oxygen requirements and frequency of exacerbations. Patients and healthcare providers
should also consider the length of travel, mode of transportation and the conditions and access to medical
care at the destination. Considerations may be different for patients required to travel for business. In such
cases, it is the responsibility of the advising physician to support their decision to avoid travelling if such a
journey may compromise their health condition. In other cases, the emphasis should be on supporting
people, even with life-limiting conditions, to enjoy travel by planning ahead.
Planning travel: are there destinations and conditions that certain people with bronchiectasis
should avoid?
Recommendation:
4) People with bronchiectasis should consult their healthcare professional regarding staying at high
altitudes (85% agreement).
Other statements considered:
• People with bronchiectasis should try to avoid travelling to places with high levels of air pollution (73%
agreement).
• People with bronchiectasis should try to avoid travelling to places with a high prevalence of
nontuberculous mycobacteria (NTM) such as Hawaii, USA (38% agreement).
• People with bronchiectasis should try to avoid travelling during influenza season (35% agreement).
• Travelling to high-altitude destinations (above 3050 m/10000 ft) should be avoided in people with
bronchiectasis (32% agreement).
• People with bronchiectasis should preferably travel to destinations with a nearby bronchiectasis centre
(31% agreement).
When staying at high altitudes above 2000 m, several environmental changes may have consequences in
people with chronic lung disease and bronchiectasis in particular. Most importantly, as barometric
pressure decreases, oxygen concentration decreases. This predisposes all individuals ascending to
TABLE 1 Continued
Statement Agree Disagree
What kind of activities may people with bronchiectasis engage in while on holiday and what precautions are
recommended?
It is recommended that people with bronchiectasis should use sun protection while using medications that
increase photosensitivity (e.g. ciprofloxacin, doxycycline)
100%
It is recommended that people with bronchiectasis take measures to avoid dehydration while in a hot climate 100%
It is advised that people with bronchiectasis maintain general measures of hygiene to prevent cross-infection:
hand hygiene, wearing face masks in crowded places
88% 12%
It is recommended that all people with bronchiectasis refrain from SCUBA diving 35% 65%
It may be safe for people with bronchiectasis to SCUBA dive if they are asymptomatic (no sputum or shortness of
breath at the time of diving) and lung function is normal (FEV1 and peak expiratory flow should both be
>80% pred, FEV1/forced vital capacity >75%)
85% 15%
It is recommended that people with bronchiectasis should be aware of their own limitations to strenuous activities
and limit their participation in such activities accordingly. This refers to sports including hiking, swimming and
snorkelling, but also less strenuous activities such as short walks uphill and climbing stairs
96% 4%
Where should people with bronchiectasis get help if they get sick while away?
Prior to travel, people with bronchiectasis should be advised on increasing airway clearance if suffering an
exacerbation while away
96% 4%
Prior to travel, people with bronchiectasis should be advised when to take antibiotics, including a recommendation
for an oral antibiotic, dose and duration
100%
People with bronchiectasis should be advised when and where to seek medical care at their destination 88% 12%
NTM: nontuberculous mycobacteria; FEV1: forced expiratory volume in 1 s; SCUBA: self-contained underwater breathing apparatus; % pred:
% predicted. #: 25 out of 26 responded; all other items had 26 responses.
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high-altitude destinations to several acute illnesses, including high-altitude pulmonary oedema [12]. In
individuals with chronic respiratory conditions causing hypoxaemia at sea level, ascending to high
altitudes may worsen hypoxaemia and predispose to respiratory and cardiac failure. While there is no
literature on people with bronchiectasis travelling to high-altitude destinations, recommendations
regarding individuals with chronic lung diseases such as asthma, COPD and CF exist [9, 12, 13] and are
largely based on exposure to high altitude during air travel. However, although the oxygen concentration
during a commercial flight is comparable to that of altitudes of ∼2000 m, there are differences in the
conditions between air travel and staying at elevated-altitude destinations, mainly the level of physical
exertion, and length of exposure to high altitude.
Based on studies in people with COPD during commercial flights and adapting these findings to
high-altitude destinations, STREAM et al. [12] recommended that travel to altitudes above 3050 m (10000 ft)
should be avoided in people with COPD. Individuals already on supplemental oxygen should continue to
use it during their high-altitude stay, but should increase the flow at rest and during exertion. Patients
with an forced expiratory volume in 1 s (FEV1) <1.5 L who are not receiving supplemental oxygen should
undergo a pre-travel evaluation (using hypoxia simulation or prediction equations; table 2) to determine
their need for supplemental oxygen at high altitude, with oxygen prescribed if the PaO2 is predicted to fall
below 50 mmHg [10]. While there are many differences between COPD and bronchiectasis, due to scarcity
of data on bronchiectasis, and because of similar age and comorbidities as people with COPD, these
recommendations can be adopted for people with severe bronchiectasis. However, the recommendation on
avoiding altitudes above 3050 m altogether did not reach agreement for all people with bronchiectasis, and
should be individualised on the basis of severity.
Pulmonary exacerbations in people with bronchiectasis are temporally linked to periods of air pollution
[14, 15]. It therefore makes sense to advise people with bronchiectasis against travelling to places with
heavy air pollution. This recommendation reached 73% agreement, with a comment that only those with
moderate to severe bronchiectasis and those who are prone to exacerbations [16] should avoid highly
polluted places. Information regarding global air quality from multiple monitoring stations is found at:
www.aqicn.org/map.
People with bronchiectasis are at risk of acquiring infections with NTM [17–21] with prevalence rates that
range from 5% [17] to 50% in different series [19]. Series from the United States, especially Hawaii,
repeatedly report an elevated prevalence of NTM pulmonary disease. However, little is known about the
risk of acquiring infection when travelling to locations with a high risk of NTM for a holiday or even for
an extended period of time. It is therefore not recommended for people with bronchiectasis to avoid
travelling to places with a high prevalence of NTM. However, this recommendation may be individualised
for people with severe bronchiectasis and features of a high risk of NTM infection [17].
When ill during travel, people with bronchiectasis may need to consult local healthcare professionals.
For people with very severe bronchiectasis, it may be advised to locate a bronchiectasis centre close to
the travel destination and even contact a specialist to inform them about the individual travelling to
their area. However, since most people with bronchiectasis may be instructed to self-manage during
exacerbations, it is not advised to restrict all individuals to travel exclusively to places with
bronchiectasis centres.
Air travel can be associated with an elevated risk of airborne infections, such as viruses. It is reasonable to
suspect that travelling during a period of a respiratory disease outbreak (such as influenza) can increase
the risk of acquiring influenza and a pulmonary exacerbation. However, while annual influenza
immunisation is advised in bronchiectasis guidelines [22], the expert panel does not recommend that
people with bronchiectasis avoid travel during influenza season. General precautions for hand hygiene and
lung health, including cough etiquette should be followed.
TABLE 2 Examples of equations for predicting hypoxaemia
PaO2 Alt=0.410×PaO2Ground+17.652
PaO2 Alt=0.519×PaO2Ground+11.855×(FEV1 L)−1.760
PaO2 Alt=0.453×PaO2Ground+0.386×(FEV1 % pred)+2.44
PaO2 Alt=22.8−(2.74×altitude in 1000s of feet)+0.68×PaO2Ground
PaO2 Alt: predicted arterial oxygen tension at altitude (in millimetres of mercury); PaO2Ground: measured
arterial oxygen tension at sea level (in millimetres of mercury); FEV1: forced expiratory volume in 1 s;
% pred: % predicted. Information from [10].
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What travel insurance should people with bronchiectasis acquire?
Recommendation:
5) People with bronchiectasis should acquire health insurance with a coverage of deterioration of a chronic
condition (100% agreement).
6) People with bronchiectasis should acquire health insurance with a coverage of hospital admission and
emergency room visits (100% agreement).
Other statement considered:
• People with bronchiectasis should acquire health insurance with coverage of repatriation (68%
agreement).
Bronchiectasis is a chronic illness punctuated by episodes of increasing signs and symptom exacerbations,
requiring a change in treatment. While most people with bronchiectasis can self-manage mild
exacerbations, the need for specialist care while away may not always be predicted. It is therefore advised
to acquire medical insurance that covers a deterioration of a chronic condition, including hospital
admission and emergency room visits, especially for those with frequent exacerbations or hospitalisations
(100% agreement). While obtaining travel insurance with a coverage of repatriation was recommended by
the majority of experts, it did not reach our consensus definition. Some experts gave the reasoning that
repatriation is not a medical need and therefore cannot be recommended. It remains at the decision of the
individual travelling to obtain this coverage.
What medications and devices should people with bronchiectasis carry with them when
travelling?
Recommendations:
7) When travelling, it is recommended that people with bronchiectasis should continue taking their
regular treatments and make arrangements to take enough medications and equipment for the duration
of their travel (100% agreement).
8) When travelling, people with bronchiectasis should consult their healthcare professional or respiratory
physiotherapist regarding possible alternatives to heavy or large equipment such as nebulisers (100%
agreement).
9) People with bronchiectasis who suffer frequent pulmonary exacerbations should consult their specialist
regarding carrying antibiotics to be used in case of a pulmonary exacerbation when travelling (100%
agreement).
10) Medications taken for travel should be properly stored according to manufacturer’s recommendations,
particularly storage temperature and light exposure (100% agreement).
11) Electricity requirements (e.g. for a nebuliser) and cleaning instructions should be known prior to
travelling and proper adaptations, including checking batteries should be planned (100% agreement).
It is advisable to provide patients with bronchiectasis with an action plan to be carried when travelling
regarding specific medications to be taken when stable and during exacerbations. Antibiotics for an
exacerbation should be based on prior sputum cultures and past exacerbation history. Instructions for
storage of common medications for bronchiectasis are summarised in table 3, and it is always advisable
for patients to refer to the package insert/summary of product characteristics. In general, it is advisable
to take the routine medication for daily care as cabin baggage due to the risk of loss when baggage has
been checked in. In addition, medication supply should exceed the planned duration of travel for 1 or
2 weeks in order to be prepared for unexpected delays in return. Nebulisers and chest wall oscillators
may be heavy and inconvenient to carry; electricity requirements may vary from place to place and
operation by batteries is only possible for some nebulisers. The appropriate means for cleaning and
sterilising medical equipment (e.g. nebulisers and mucus-clearance devices) should be available when
travelling.
Likewise, carrying parenteral antibiotics may require special storage conditions. It should be discussed with
the healthcare provider whether maintaining inhalation therapy is required for the time away, and if
possible, switching to a portable nebuliser or metered dose inhaler if appropriate.
Airway clearance during travel needs to be individualised. Some patients can skip a day or two of airway
clearance, others can modify to a “simpler” programme for a few days, whereas other patients need to be
strictly adherent to their airway clearance program whether at home or travelling. It is possible to switch
to an airway clearance regime that requires small, lightweight devices. For example, it may be easy to
perform autogenic drainage (which does not require carrying any equipment), or alternatively carrying
small and lightweight positive expiratory pressure devices. Some airway clearance techniques can make use
of inexpensive everyday objects (tube-in water bottle positive expiratory pressure or drinking straws).
Planning ahead is always recommended and should be done with the advice and direction of the
healthcare provider.
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TABLE 3 Storage conditions for common medications for bronchiectasis
Drug name Common trade names in Europe Storage conditions Comments
Oral antibiotics and antifungals
Azithromycin Cap. azithromycin 250 mg
Cap. Azenil 250 mg
Cap. azithromycin Inovamed 250 mg
Cap. Zithromax 250 mg
Tab. Zeto 250 mg
Tab. azithromycin 250 mg
Cap., tab.: store in the original package in
order to protect from light; store below
25°C
Skin photosensitivity: uncommon (⩽1%)
Alcohol: no special recommendation
Azenil 200 mg/5 mL powder for oral susp.
Azithromycin 200 mg/5 mL powder for
oral susp.
Azithromycin Teva 200 mg/5 mL powder for
oral susp.
Zithromax 200 mg/5 mL powder for
oral susp.
Powder for susp.: store below 25°C
Reconstituted susp.: store at room
temperature, below 25°C
After reconstitution of the powder, use the
susp. within 5 days; shake immediately
prior to use
Erythromycin Tab. erythromycin 250 mg
Tab. Erythro Teva 250 mg; 500 mg
Tab. Erythrocin 250 mg; 500 mg
Tab. Erythroped A 500 mg
Tab.: store in a dry place, below 25°C Alcohol: may decrease the absorption of
erythromycin or enhance effects of
alcohol (ethanol); the combination should
be avoided
Erythromycin SF granules for oral
susp. 125 mg/5 mL; 250 mg/5 mL;
500 mg/5 mL
Erythromycin ethyl succinate granules for
oral susp. 125 mg/5 mL; 250 mg/5 mL;
500 mg/5 mL
Erythroped SF 250 mg/5 mL; 500 mg/5 mL
Primacine granules for oral susp. 250 mg/
5 mL
Granules for susp.: store below 25°C
Reconstituted susp.: store in a refrigerator
(2–8°C); do not freeze
After reconstitution, use the suspension
within 14 days; shake immediately prior
to use
Roxithromycin Tab. Rulid 150 mg; 300 mg
Tab. Roxo 150 mg
Tab.: store below 25°C Alcohol: no special recommendation
Clarithromycin Tab. Karin 250 mg, 500 mg
Tab. Klacid SR 500 mg
Tab. clarithromycin 250 mg, 500 mg
Tab. Klaricid XL 500 mg
Prolonged release tab. Mycifor XL 500 mg
Caplets Klaridex 250 mg
Tab., caplets: store in the original package
in order to protect from light and
moisture; store below 25°C (some
manufacturers permit excursions up to
30°C)
Alcohol: no special recommendation
Sachet Klaricid adult 250 mg Sachet: store in a dry place, below 30°C
Mix the contents of the sachet with a small
amount of water before taking to make
the granules easier to swallow
Klacid paediatric granules for
susp. 125 mg/5 mL
Susp. Clarithromycin 125 mg/5 mL; 250 mg/
5 mL
Oral susp. clarithromycin 125 mg/5 mL;
250 mg/5 mL
Klaricid paediatric susp. 125 mg/5 mL;
250 mg/5 mL
Granules for susp.: store below 30°C
Reconstituted susp.: store at room
temperature, below 25°C (up to 30°C
according to manufacturer) and use
within 14 days from reconstitution; do not
refrigerate or freeze the reconstituted
suspension; shake immediately prior
to use
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Amoxicillin Cap. amoxicillin 250 mg; 500 mg
Cap. Amoxil 250 mg; 500 mg
Cap. Moxyvit 250 mg
Cap. Moxyvit forte 500 mg
Cap. Moxypen forte 500 mg
Cap.: store in a dry place, below 25°C Alcohol: no special recommendation
Amoxicillin powder for oral susp. 125 mg/
5 mL; 250 mg/5 mL
Amoxicillin powder for oral susp. SF
125 mg/5 mL; 250 mg/5 mL
Moxyvit forte powder for oral susp. 250 mg/
5 mL
Moxypen forte powder for susp. 250 mg/
5 mL
Powder for susp.: store in a dry place,
below 25°C
Reconstituted susp.: according to
manufacturer instructions, store in a
refrigerator (2–8°C) or at room
temperature (below 25°C) and use within
7–14 days#; shake immediately prior
to use
Amoxicillin–clavulanic acid Tab. Amoxiclav Teva 875 mg
Tab. Augmentin 250 mg; 500 mg; 875 mg
Tab. co-amoxiclav 250 mg; 500 mg
Tab. Maclivan 500 mg
Tab.: store in the original package in order
to protect from moisture; store below 25°C
Augmentin tab. supplied in an aluminium
pouch should be used within 30 days of
opening the pouch
Alcohol: no special recommendation
Augmentin powder for oral susp. 250 mg/
5 mL; 400 mg/5 mL
Augmentin ES Augmentin powder for oral
susp. 600 mg/5 mL
Co-amoxiclav powder for oral suspension
125 mg/5 mL; 250 mg/5 mL; 400 mg/
5 mL
Maclivan powder for oral suspension
250 mg/5 mL; 400 mg/5 mL
Powder for susp.: store in the original
package in order to protect from
moisture; store below 25°C
Reconstituted susp.: according to
manufacturer instructions, store in a
refrigerator (2–8°C) and use within
7–10 days#
Doxycycline Cap. Doxy 100 mg
Cap. doxycycline 50 mg; 100 mg
Cap. Vibramycin Hyclate 100 mg
Tab. Doxylin 100 mg
Vibramycin-D 100 mg Dispersible tabs
Vibra-Tabs 100 mg
Cap., tab.: store in the original package in
order to protect from light and moisture;
store below 25°C#
Skin photosensitivity: sunlight or ultraviolet
light exposure increases the risk of
photosensitivity; use skin protection and
avoid prolonged exposure to sunlight and
ultraviolet light; avoid use of tanning
equipment.
Discontinue the treatment at first sign of
skin erythema
Alcohol: ingestion may shorten the half-life
of doxycycline and reduce its serum
concentration; the combination should be
avoided
Doxycycline powder for susp. 25 mg/5 mL
Vibramycin monohydrate powder for
susp. 25 mg·mL−1
Powder for susp.: store in the original
package in order to protect from light
and moisture; store below 25°C#
Reconstituted susp.: store in the original
package in order to protect from light
and moisture; store below 25°C (up to
30°C according to manufacturer); use
within 14 days from reconstitution; shake
immediately prior to use
Vibramycin calcium syrup 50 mg·mL−1 Syrup: store in the original package in
order to protect from light and moisture;
store below 30°C
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Minocycline Cap. minocycline 50 mg; 100 mg
Cap. Minoclin 100 mg
Tab. minocycline 50 mg; 100 mg
Cap., tab.: store in the original package in
order to protect from light; store below
25°C
Skin photosensitivity: may cause
photosensitivity; use skin protection and
avoid prolonged exposure to sunlight and
ultraviolet light; avoid use of tanning
equipment
Discontinue the treatment if skin erythema
occurs
Alcohol: no special recommendation
Cefuroxime Tab. Zinnat 125 mg; 250 mg; 500 mg
Tab. Cefuroxime 250 mg
Tab. store in the original package in order
to protect from moisture; store below 30°C
Alcohol: no special recommendation
Zinnat powder for oral susp. 125 mg/5 mL;
250 mg/5 mL
Powder for suspension: store in the original
package, below 30°C
Reconstituted susp.: store in a refrigerator
(2–8°C); do not freeze
After reconstitution, use the susp. within
10 days; shake the bottle vigorously
before the medication is taken
Cephalexin Cap. Cefovit 250 mg; forte 500 mg
Cap., tab. Cefalexin 250 mg; 500 mg
Tab. Keflex 250 mg; 500 mg
Cap.: store in a dry place, below 25°C Alcohol: no special recommendation
Cefovit powder for oral susp. 125 mg/5 mL;
Cefovit forte 250 mg/5 mL
Cefalexin granules for oral susp. 125 mg/
5 mL; 250 mg/5 mL
Keflex granules for oral susp. 125 mg/5 mL;
250 mg/5 mL
Powder/granules for susp.: store in a dry
place, below 25°C
Reconstituted susp.: according to
manufacturer instructions, store in a
refrigerator (2–8°C) and use within
10–14 days#; shake well before each use
SMX-TMP Caplets Diseptyl forte 800 mg/160 mg
Tab. co-trimoxazole 400 mg/80 mg
Tab. co-trimoxazole forte 800 mg/160 mg
Tab. Septrin 400 mg/80 mg
Tab. Septrin forte 800 mg/160 mg
Cap., tab.: store in the original package,
below 25°C
Skin photosensitivity: as been reported with
SMX-TMP; use with caution; use skin
protection and avoid prolonged exposure
to sunlight and ultraviolet light; avoid use
of tanning equipment
Discontinue the treatment if skin erythema
occurs
Alcohol: a disulfiram-like reaction (flushing,
sweating, palpitations and drowsiness)
may occur if alcohol (0.5–1 L of an
alcoholic drink e.g. beer) is ingested
Susp. Diseptyl 200 mg/40 mg in 5 mL
Co-trimoxazole paediatric susp. 200 mg/
40 mg in 5 mL
Co-trimoxazole adult susp. 400 mg/80 mg
in 5 mL
Septrin paediatric susp. 200 mg/40 mg in
5 mL
Septrin adult susp. 400 mg/80 mg in 5 mL
Susp. Store in a dark and dry place, below
25°C
Use within 10 days of opening#.
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Ciprofloxacin Tab. Ciprodex 250 mg; 500 mg; 750 mg
Tab. ciprofloxacin Teva 250 mg; 500 mg;
750 mg
Ciprofloxacin 100 mg; 250 mg; 500 mg;
750 mg film-coated tab.
Tab. Ciproxin 500 mg
Tab. store in the original package, below
25°C
Skin photosensitivity: ciprofloxacin has been
shown to cause photosensitivity reactions;
use skin protection and avoid prolonged
exposure to sunlight and ultraviolet light;
avoid use of tanning equipment
Discontinue the treatment if skin erythema
occurs
Caffeine: ciprofloxacin has been shown to
interfere with the metabolism of caffeine
leading to increased caffeine
concentrations; patients consuming
regular large quantities of caffeinated
beverages may need to restrict caffeine
intake if excessive cardiac or central
nervous system stimulation occurs; the
effect of this interaction is greater in
females
Ciproxin 250 mg/5 mL, granules and
solvent for oral susp.
Ciproxin: store the granules and solvent
below 25°C; protect the solvent from
freezing; avoid inverted storage
The ready-to-use oral susp. (utilising the
individual components) is stable only for
14 days when either stored in a
refrigerator (2–8°C) or at temperatures
up to 30°C; protect the reconstituted
susp. from freezing
Moxifloxacin Tab. Megaxin 400 mg
Tab., film-coated Moxicloxacin 400 mg
Tab. Avelox 400 mg
Tab.: store in the original package in order
to protect from moisture; store below 25°C
Skin photosensitivity: quinolones have been
shown to cause photosensitivity reactions
in patients; use skin protection and avoid
prolonged exposure to sunlight and
ultraviolet light; avoid use of tanning
equipment
Discontinue the treatment if skin erythema
occurs
Fluconazole Cap. Flucanol 50 mg; 100 mg; 150 mg;
200 mg
Cap. fluconazole Teva 150 mg
Cap. Trican 50 mg, 100 mg, 150 mg, 200 mg
Cap. fluconazole/Azocan 50 mg, 150 mg,
200 mg
Cap.: store in a dry place below 25°C# Alcohol: no special recommendation
Fluconazole powder for oral susp. (Genus
Pharmaceuticals) 50 mg/5 mL
Diflucan powder for oral suspension
10 mg/mL; 40 mg/mL
Powder for susp.: store in a dry place,
below 25°C
Reconstituted susp. store in a refrigerator
(2–8°C) or at temperatures up to 30°C
use within 14–28 days#; protect the
reconstituted susp. from freezing; shake
well before administration
Itraconazole Cap. Itranol 100 mg
Cap. itraconazole 100 mg
Cap.: store in the original package in order
to protect from moisture; store below 25°C
Skin photosensitivity: uncommon (⩽2%);
case reports have been described
Use skin protection and avoid prolonged
exposure to sunlight and ultraviolet light;
avoid use of tanning equipment
Discontinue the treatment if skin erythema
occurs
Alcohol: no special recommendation
Cap. Sporanox Sporanox cap.: up to 30°C
Sporanox oral solution 10 mg·mL−1 Powder for susp.: store below 25°C; use
within 30 days of openingItraconazole 10 mg·mL−1 oral solution
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Expectorants and cough
suppressants
Acetylcysteine Reolin effervescent tablets 200 mg
Siran 200 mg effervescent tablets
Effervescent tablets: store in the original
package in order to protect from
moisture; store below 25°C; close the
tube immediately after taking out the
tablet
After dissolving the tablet, it must be used
immediately
Reolin: use within 2 years after the first
opening or until the expiry date
Siran: use within 4 weeks after the first
opening
Alcohol: no special recommendation
Sachet acetylcysteine 200 mg powder for
oral solution
Powder for oral solution: store in the
original package in order to protect from
moisture
Reconstituted solution: the product must be
used immediately
Guaifenesin Resyl syrup 100 mg/5 mL (contains 6%
alcohol by volume)
Benylin syrup for children’s chesty coughs
50 mg/5 mL
Benylin syrup Mucus Cough Max honey and
lemon flavour 100 mg/5 mL (contains
4.7% alcohol by volume)
Oral solution Benylin Mucus Cough Max
menthol flavour 100 mg/5 mL (contains
4.7% alcohol by volume)
Boots chesty cough relief 100 mg/5 mL oral
solution
Boots chesty cough syrup 6 years plus
(contains alcohol)
Boots mucus cough relief 100 mg/5 mL oral
solution
Covonia chesty cough SF syrup
Robitussin chesty cough medicine 100 mg/
5mL−1 oral solution (contains 2.7% v/v
alcohol)
Lemsip cough for chesty cough 50 mg/5 mL
oral solution
Syrup: store in the original package,
below 25°C
Resyl: store below 30°C; use within
6 months of opening
Benylin honey and lemon flavour: use within
6 months of opening
Oral solution: store below 25°C
Benylin menthol flavour: store in the
original container to protect from light
and use within 4 weeks of opening
Alcohol: some products contain alcohol;
therefore, these formulations can
emphasise the effect of sedatives
(including alcohol) and myorelaxants
Avoid concurrent use or use caution when
motor skills are required
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Other oral medications
Prednisone Tab. prednisone 1 mg; 5 mg; 20 mg
Modified-release tab. Lodotra 1 mg;
2 mg; 5 mg
Tab.: store in a dark and dry place,
below 25°C
Tab. prednisone 1 mg: use within 2 months
of opening (but not after the expiry date)
Lodotra: store below 25°C and use within
14 weeks of opening (but not after the
expiry date)
Alcohol: no special recommendation
Prednisolone Tab. Pevanti 2.5 mg; 5 mg; 10 mg;
20 mg; 25 mg
Tab. prednisolone 1 mg, 2.5 mg; 5 mg;
10 mg; 20 mg; 25 mg; 30 mg
Tab. prednisolone gastro-resistant 1 mg;
2.5 mg; 5 mg
Soluble tab. prednisolone 5 mg
Tab. (also gastro-resistant and soluble tab.):
store in the original package in order to
protect from light and moisture, below
25°C
Pevanti: use within 6 months of opening
(but not after the expiry date)
Alcohol: some products contain alcohol;
avoid concurrent use of ethanol with
these formulations or use caution when
motor skills are required
Danalone syrup 15 mg/5 mL (contains
alcohol)
Syrup: store below 25°C but not in the
refrigerator; close firmly, and prevent
penetration of air and moisture
Prednisolone Dompe 1 mg·mL−1 oral
solution (single-dose containers)
Prednisolone 10 mg·mL−1 oral solution
Dompe: before opening, store in the original
package; store below 30°C
Once opened, the container must be
discarded once the dose is removed
Prednisolone 10 mg·mL−1: keep the
container in the outer carton in order to
protect from light
Before opening, store in a refrigerator
(2–8°C)
Once opened, store below 25°C and use
within 3 months
Proton pump inhibitors
Omeprazole Caplets Omepradex 10 mg; 20 mg; 40 mg
Caplets Omepradex-Z 20 mg
Caplets: store in the original package,
below 25°C
Skin photosensitivity: has been described
but is rare (⩽0.1%)
Alcohol: no special recommendationCap. Losec 20 mg (Israel)
Cap. Omepra 10 mg; 20 mg; 40 mg
Cap. Omeprix 20 mg
Cap. Losec 10 mg; 20 mg; 40 mg (Europe)
Cap. Mepradec gastro-resistant 10, 20 mg
Cap. Omeprazole gastro-resistant 10 mg;
20 mg; 40 mg
Cap. Prenome 10 mg; 20 mg; 40 mg
Cap. Omeprazole 10 mg; 20 mg; 40 mg
Tab. Omeprazole Gastro-resistant 10 mg;
20 mg; 40 mg
Pyrocalm Control 20 mg gastro-resistant
tablets
Cap., tab.: store below 25°C
Store in the original package in order to
protect from moisture, below 25–30°C
and use within 3 months of opening of
the bottle#
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Esomeprazole Tab. esomeprazole Inovamed 20 mg; 40 mg
Tab. Nexium 20 mg; 40 mg
Tab. esomeprazole gastro-resistant 20 mg;
40 mg
Cap. Emozul gastro-resistant 20 mg, 40 mg
Cap. esomeprazole gastro-resistant 20 mg;
40 mg
Ventra gastro-resistant capsules 20 mg;
40 mg
Tab., cap.: store in the original package in
order to protect from moisture
Store below 25–30°C# and use within
3–6 months after first opening of the
bottle#
Skin photosensitivity: has been described in
the literature but is rare (⩽0.1%)
Alcohol: no special recommendation
Sachet Nexium 10 mg gastro-resistant
granules for oral susp.
Granules for oral susp.: use within 30 min
after reconstitution
Lansoprazole Cap. lansoprazole 15 mg; 30 mg
Cap. Lanton 15 mg; 30 mg
Cap. lansoprazole gastro-resistant 15 mg;
30 mg
Orodispersible tab. lansoprazole 15 mg;
30 mg
Zoton Fas-Tab 15 mg; 30 mg
Cap., tab.: store in the original package in
order to protect from light and moisture;
store below 25°C
Use within 2 months to 100 days after first
opening of the bottle#
Skin photosensitivity: has been described in
the literature but is rare (⩽0.1%)
Alcohol: no special recommendation
Pantoprazole Tab. Contrololc 20 mg; 40 mg
Pantoloc Control 20 mg gastro-resistant
tablets
Tab. Pantoprazole gastro-resistant 20 mg;
40 mg
Tab. store in the original package in order
to protect from moisture; store below 25°C
Use within 6 months after first opening of
the bottle#
Skin photosensitivity: has been described in
the literature (but the frequency cannot
be estimated from the available data);
use with caution
Alcohol: no special recommendation
H2 blockers
Famotidine Tab. famotidine Teva 20 mg; 40 mg
Tab. Famo 20 mg; 40 mg
Tab. Gastro 10 mg; 20 mg; 40 mg
Tab. Pepcid 20 mg; 40 mg
Tab. store in the original package in order
to protect from light and moisture; store
below 25°C
Alcohol: no special recommendation
Pepcid powder for oral susp. 40 mg/5 mL Powder for susp.: store in the original
package at 25°C; excursions permitted to
15–30°C
Reconstituted susp.: after reconstitution,
use the suspension within 30 days;
protect from freezing
Ranitidine Tab. Zaridex 150 mg; 300 mg
Tab. Ranitidine film-coated 150 mg; 300 mg
Tab. Zantac 75 mg; 150 mg; 300 mg
Tab.: store in the original package,
below 25°C
Alcohol: co-ingestion of alcohol (1.5–2
drinks) while on ranitidine may result in
higher blood alcohol concentrations,
although the clinical significance is
uncertain
In addition, some products contain alcohol;
avoid concurrent use of ethanol with
these formulations or use caution when
motor skills are required
Zantac syrup 150 mg/10 mL (contains
∼7.5% w/v alcohol)
Syrup: store below 25°C and use within
28 days of opening
Ranitidine 150 mg/10 mL oral solution
(contains ∼8% w/v alcohol)
Ranitidine 30 mg·mL−1 oral solution
(contains ∼7.5% w/v alcohol)
Oral solution: store in original carton/bottle
in order to protect from light; store
below 25°C
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Antacids
Aluminium hydroxide,
magnesium hydroxide and
dimethicone/simethicone
Maalox Plus chewable tablets (200 mg
magnesium hydroxide, 200 mg hydrated
aluminium oxide and 25 mg dimethicone
in a tablet)
Tab.: store in the original package, below
25°C
Alcohol: no special recommendation
Maalox Plus oral susp. (225 mg aluminium
hydroxide, 200 mg magnesium hydroxide
and 25 mg simethicone in 5 mL)
Oral susp.: store below 25°C and use within
28 days of opening; shake well before
administration
Calcium carbonate Chewable tab. Tums
Chewable tab. N-Zarevet
Chewable tab.
Chewable tab.: store in the original
package, below 25°C
N-Zarevet: use within 12 months after first
opening of the bottle
Alcohol: no special recommendation
Calcium carbonate and
magnesium carbonate
Chewable tab. Rennie
Chewable tab. Rolaids
Chewable tab.: store in the original
package, below 25°C
Alcohol: no special recommendation
Rolaids mint liquid (550 mg calcium
carbonate and 110 mg magnesium
hydroxide in 5 mL)
Liquid: do not freeze
Calcium carbonate, sodium
bicarbonate and sodium
alginate
Chewable tab. Gaviscon Chewable tab.: store in the original package
in order to protect from moisture; below
25–30°C#
Alcohol: no special recommendation
Gaviscon peppermint liquid Liquid: store in the original package, below
25–30°C (according to manufacturer
instructions) and use within 6 months of
opening
Gaviscon liquid sachets mint flavour
(500 mg sodium alginate, 267 mg sodium
bicarbonate and 160 mg calcium
carbonate per 10-mL dose)
Liquid sachet: store in the original package,
below 25°C; discard any unused contents
Bronchodilators: inhalers and
solution
Salbutamol MDI Ventolin inhaler CFC-Free 100 µg per dose
Salbutrim CFC-free inhaler 100 µg per dose
Ventolin, Salbutrim: store below 30°C;
protect from frost and direct sunlight
If the inhaler gets very cold, take the
metal container out of the plastic case
and warm it in your hands for a few
minutes; do not use anything else to
warm it up
Alcohol: no special recommendation
Easyhaler Salbutamol 100 µg per dose,
200 µg per dose
Salamol Easi-Breathe 100 µg per dose
Easyhaler: store in a dry place, at a
temperature below 25°C; use within
6 months after first opening of foil pouch
Salbulin MDPI Novolizer Salbulin: store below 30°C; use within
6 months after first opening the container
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Ipratropium MDI MDI Atrovent 20 µg per dose MDI: store below 25°C (Europe) or 30°C
(Israel); protect from frost and direct
sunlight; do not expose to temperature
>50°C
Alcohol: no special recommendation
Salbutamol (solution) Ventolin respirator solution 5 mg·mL−1
(0.5% w/v)
Ventolin respirator solution: store below
25–30°C#; protect from light; discard any
contents remaining 1 month after opening
the bottle
A fresh solution should be prepared before
each usage
Alcohol: no special recommendation
Ventolin Nebules 2.5 mg/2.5 mL (0.1% w/v),
5 mg/2.5 mL (0.2% w/v)
Ampules Salbutamol 2.5 mg/2.5 mL
nebuliser solution; 5 mg/2.5 mL
Ventolin Nebules, Ampules Salbutamol:
store below 25–30°C#; protect from light
after removal from the foil overwrap
pouch
Use nebules 3 months after removal from
the foil pouch; use immediately after first
opening of the ampule and discard any
unused contents
Ipratropium (solution) Aerovent respirator solution 0.25 mg·mL−1 Respirator solution: store below 25°C; do
not freeze
Discard any contents remaining 1 month
after opening the bottle
A fresh solution should be prepared before
each usage
Alcohol: no special recommendation
Atrovent 250 UDVs, 1 mL; Atrovent UDVs,
2 mL–0.25 mg·mL−1 vials
Ampules ipratropium bromide 250 µg/1 mL
nebuliser solution; 500 µg/2 mL nebuliser
solution
Atrovent 250 UDVs, Atrovent UDVs, Ampules
Ipratropium bromide: keep the vials in
the outer carton; store below 25°C
Use immediately after first opening of the
ampule and discard any unused contents
Other inhaled medications
Isotonic saline (sodium
chloride 0.9% w/v)
Ampules sodium chloride 0.9% Fresenius
5 mL; 10 mL; 20 mL per ampule
Saline nebuliser solution Arrow 2.5 mL per
ampule
Saline Steripoules 2.5 mL
Ampules: store below 25°C; do not
refrigerate or freeze
Saline nebuliser solution
Strips of 10 ampules are overwrapped in an
aluminium foil pack; ampules removed
from the foil overwrap should be used
within 90 days
Alcohol: no special recommendation
Hypertonic saline (sodium
chloride 3%, 6%, 7% w/v)
INH Solution MucoClear (sodium chloride)
3%, 4 mL per ampule
INH Solution MucoClear (sodium chloride)
6%, 4 mL per ampule
MucoClear: store below 25°C; do not
refrigerate or freeze
Alcohol: no special recommendation
INH Solution PulmoSal 7%, (pH+) 4 mL
per vial
Pulmosal: store at room temperature,
15–30°C; avoid excessive heat and protect
from freezing
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Inhaled antimicrobials
CMS Vial Coliracin 1000000 units per vial
Vial CMS 1000000 IU powder for solution
for injection
Vial Colomycin 1000000 IU, 2 million IU
Promixin, 1000000 IU powder for nebuliser
solution
Vial: store below 25°C; protect from light
Use immediately after reconstitution with
0.9% sodium chloride; solutions may be
used within 24 h when stored in a
refrigerator (2–8°C)
Alcohol: no special recommendation
Colobreathe 1662500 IU inhalation powder,
hard capsules (∼125 mg CMS)
Colobreathe: store in the original package
until immediately before use in order to
protect from moisture; store below 25°C
Tobramycin Vial tobramycin 40 mg·mL−1 solution for
injection
Vial for injection: store in the outer carton
in order to protect from light; store
below 25°C
Use immediately after reconstitution with
0.9% sodium chloride
Solutions may be used within 24 h when
stored in a refrigerator (2–8°C)
A fresh solution should be prepared before
each usage
Alcohol: no special recommendation
Vial Nebcin injection 40 mg·mL−1 Ready-to-use nebuliser solution: store in
the original package in order to protect
from light and moisture; store in a
refrigerator (2–8°C); do not freeze
Bramitob 300 mg/4 mL nebuliser solution,
single-dose container
The contents of the whole ampule should
be used directly after opening; opened
ampules should never be stored for
re-use
TOBI Podhaler 28 mg per capsule inhalation
powder, hard capsules
TOBI pouch, Tymbrineb foil pouch,
Tobramycin pouch (intact or opened);
may be stored at room temperature (up
to 25°C) for up to 28 days
TOBI 300 mg/5 mL nebuliser solution,
single-use ampule
Bramitob bags (intact or opened) may be
stored at room temperature (up to 25°C)
for up to 3 months
Vantobra pouch (intact or opened) may be
stored at room temperature (up to 25°C)
for up to 4 weeks
TOBI Podhaler 28 mg per capsule inhalation
powder
Capsules for inhalation: TOBI Podhaler
capsules must always be stored in the
blister to protect from moisture and only
removed immediately before use; store
below 30°C
Podhaler device: store the inhaler in its
tightly closed case when not in use; each
Podhaler device and its case are used for
7 days and then discarded and replaced
Continued
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TABLE 3 Continued
Drug name Common trade names in Europe Storage conditions Comments
Gentamicin Ampule gentamicin B. Braun 1 mg·mL−1;
3 mg·mL−1 solution for infusion
Ampule gentamicin 10 mg·mL−1 solution
Ampule Genticin 40 mg·mL−1 injectable
Ampule Cidomycin 80 mg/2 mL solution for
injection
Ampules for injection: store in the outer
carton in order to protect from light;
store below 25°C; use immediately after
reconstitution with 0.9% sodium chloride;
a fresh solution should be prepared
before each usage
Alcohol: no special recommendation
Cap: capsules; tab: tablets: susp.: suspension; SF: sugar free; SR: sustained release; SMX: sulfamethoxazole; TMP: trimethoprim; MDI: metered-dose inhaler; CFC: chlorofluorocarbon;
CMS: colistimethate sodium.#: see leaflet, as different instructions for different manufacturers [23].
https://doi.org/10.1183/23120541.00113-2019
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How can people with bronchiectasis maintain regular treatment when in transport?
Statements considered:
• It is advised that airway clearance and inhalations be performed while waiting at airports before and
after flights. This is best planned ahead and checked with the airport for the best place to do this (77%
agreement).
• While it is not advised to take cough suppressants for bronchiectasis, it may be considered for long
flights where a cough may be disturbing to other passengers (35% agreement).
Some patients may want to avoid coughing and having to clear secretions during flights (or long travel by
bus or train). In these cases, airway clearance may best be performed before and after flights. Since most
airports may not have private facilities, practicing airway clearance at the airport should be planned ahead.
Although no evidence exists on safety of cough suppressants, they are ill advised in bronchiectasis, and
cannot be recommended, even during flights: 65% of experts specifically advised against the use of cough
suppressants.
Do people with bronchiectasis need to prepare and carry certain documents?
Recommendations:
12) It is advised that people with bronchiectasis carry documentation from their last clinic/hospitalisation
visit, translated into English and preferably also into the language of the country of destination (81%
agreement).
13) A document for travel may be prepared and should include: patient’s health status, allergies, chronic
bacterial infections, regular medications and devices used regularly, and recommended medications
during exacerbations (100% agreement).
14) It is advised that people with bronchiectasis carry a translation of a disability card (such as a European
Union disability parking card) if eligible and where available (84% agreement).
Other statement considered:
• When travelling in a guided tour, it is advised that people with bronchiectasis should notify the travel
company of their condition (69% agreement).
Documentation may be required for airport security staff and customs officials regarding medical
equipment, but also for medical professionals in case of need. A recommended template for such
documentation adapted from HIRCHE et al. [6] is provided in the supplement. The need to notify the travel
company would depend on the severity of the disease and need for supplemental oxygen or disability.
Likewise, it is advisable to check for custom requirements regarding medication and technical equipment
with airport or custom authorities or travel agencies in advance. During guided tours, patients may need
special consideration regarding the time and place for performing daily treatments and may wish to notify
the guided tour organisers.
What are the oxygen requirements on the flight and at the travel destination?
Recommendations:
15) Oxygen requirements during commercial flights should be predicted before the flight (100%
agreement).
16) When planning travel to destinations between 2000 and 3050 m, considerations as for commercial
flights should be made (92% agreement).
Other statements considered:
• In people with an FEV1 <55% or oxygen saturation <93% at ambient air, a hypoxic challenge test
should be performed (77% agreement).
• In people with FEV1 <1.5 l, hypoxia inhalation test should be performed (56% disagreed)
In commercial flights, cabin air pressure is similar to 2000 m elevation; therefore conditions may aggravate
hypoxemia in people with chronic lung conditions. Prediction of hypoxemia during flight may be advised
for people with low lung capacity not already using oxygen supplementation, and supplemental oxygen
prescribed if predicted arterial oxygen pressure is below 50 mmHg [10]. In some countries the hypoxia
challenge test is not widely available; in such circumstances, the prediction of hypoxaemia at cabin altitude
using equations is possible (table 2). For patients already using oxygen, it is advised to increase the flow. It
is always necessary to notify the airline company in advance regarding oxygen requirements during flight.
Information regarding air travel for people with chronic lung diseases is available at the ELF website: www.
europeanlung.org/en/lung-disease-and-information/air-travel/ and www.europeanlung.org/assets/files/en/
publications/air-travel-web.pdf (available in 18 languages).
How else can people with bronchiectasis be prepared to travel?
Recommendations:
17) It is recommended that people with bronchiectasis seek advice for travellers and follow recommended
immunisations for the destination (100% agreement).
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18) Recommended medications while travelling (such as for the prevention of malaria) should be checked
for interactions with regular treatments and with treatments during exacerbations (100% agreement).
19) It is recommended that people with bronchiectasis should be stable prior to travelling, if symptoms
typical for an exacerbation develop shortly before travelling, treatment should be started and travel
postponed if possible (96% agreement).
Other statement considered:
• People with severe bronchiectasis and chronic Pseudomonas aeruginosa infection may be advised to
receive treatment with an intravenous antibiotic course shortly before travelling to prevent an
exacerbation while away (50% agreement).
When travelling to areas endemic for infectious diseases, people with bronchiectasis should consult expert
advice and/or travel clinic healthcare workers regarding immunisations and medications for preventing
infections. In people with bronchiectasis secondary to a primary immune deficiency, there is a need to
consider both the safety of live attenuated vaccines (yellow fever vaccine for example) [24], and the
efficacy of vaccinations. Mefloquine for the prevention of malaria has the potential to elongate the
QT-interval, and may increase the risk for cardiac arrhythmias especially if combined with
fluoroquinolones or azithromycin. Some patients with chronic Pseudomonas infection feel better for
several weeks after a course of anti-pseudomonal antibiotic (intravenous or oral). In very certain cases of
people with frequent exacerbations, treatment with such an antibiotic course may be considered before
travelling to prevent an exacerbation, but there is no evidence to recommend this, with the concern for
causing an emergence of resistant strains with unnecessary antibiotic treatment.
What kind of activities can people with bronchiectasis engage in while travelling and what
precautions are recommended?
Recommendations:
20) It is recommended that people with bronchiectasis should use sun protection while using medications
that increase photosensitivity, such as ciprofloxacin and doxycycline (100% agreement).
21) It is recommended that people with bronchiectasis take measures to avoid dehydration while in a hot
climate (100% agreement).
22) It is advised that people with bronchiectasis maintain general measures of hygiene to prevent
cross-infection, such as hand hygiene in crowded places (88%).
23) It may be safe for people with bronchiectasis to SCUBA dive if they are asymptomatic (no sputum or
shortness of breath at the time of diving), do not have cystic bronchiectasis, and lung function is normal
(FEV1 and peak expiratory flow should both be >80%, FEV1/forced vital capacity>75%) (85%
agreement).
Other statement considered:
• It is recommended that all people with bronchiectasis refrain from SCUBA diving (35% agreement).
Many people travel for leisure purposes, during which time they engage in activities, including sports, to
which they may be unaccustomed to. Staying and performing strenuous activities, such as hiking, in hot
climates carries a risk of dehydration, which is to be avoided in people with bronchiectasis (as hydration is
important for mucus clearance). In fact, as a general recommendation, patients with bronchiectasis should
avoid dehydration at all times. People with bronchiectasis who take medications which cause
photosensitivity, such as ciprofloxacin and doxycycline (table 3) should be advised to use measures for sun
protection and avoidance of direct sun exposure. Likewise, interaction with alcoholic beverages should be
noted, as in some cases alcohol consumption may be increased during vacations. Staying in crowded
places carries a risk of acquiring airborne infections; it is advised to use hand hygiene and avoid sharing
items such as blankets, drinking equipment, silverware and earphones. There is no evidence to support the
efficacy of wearing face masks. Due to the inconvenience and possibly stigma associated with wearing face
masks [5], their use is not recommended.
SCUBA diving is an increasingly popular recreational activity among individuals, including people with
chronic conditions and older age [25, 26]. During underwater diving, ambient pressure increases by 1 atm
(100 kPa) for every 10 m descended. Gas volumes change with the depth of diving, compressing during
descent and expanding during ascent. The partial pressure of gases increases with the increase in
hydrostatic pressure. Nitrogen, an inert gas, dissolves in tissues at depth and comes out of solution on
ascent. Another aspect of diving is that the work of breathing increases during diving due to increased gas
density, increased hydrostatic pressure, and altered respiratory mechanics (increased dead space and
resistance to breathing caused by SCUBA breathing apparatus). The risks associated with diving include:
1) barotrauma caused by expansion of gas-filled spaces during ascent; 2) Compression of the lungs during
descent which can cause alveolar exudation and haemorrhage; and 3) Expansion of the lungs during
ascent that can cause tearing of structures and lead to pneumothorax, pneumomediastinum and arterial
gas embolism. In bronchiectasis, mucus in airways or lung cysts can cause air trapping which may be
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associated with an elevated risk of barotrauma. Recommendations on medical fitness for diving [7] advise
against diving in people with pulmonary cysts or bullae, in people with asthma unless they are
asymptomatic with a normal spirometry, and in people with CF and pulmonary involvement. Similar
recommendations are given by the South Pacific Underwater Medicine Society (www.spums.org.au/
content/spums-full-medical-0) while other national diving recommendations recommend against diving in
people with bronchiectasis [11]. However, due to the large heterogeneity of bronchiectasis, only 35% of
bronchiectasis experts in our survey answered that all people with bronchiectasis should refrain from
SCUBA diving. The majority assumed it may be safe for people with mild bronchiectasis to dive provided
they are asymptomatic, with normal spirometry and no lung cysts evident on computed tomography (85%
agreement).
Although it may be intuitively tempting to advise limiting diving to shallow depths for people with
bronchiectasis, there is no physiological basis to support this recommendation: any change in depth poses
a similar risk, and most diving-related injuries occur at relatively shallow depths [7, 27].
Many other recreational sports and activities (SCUBA diving included, but also water surfing, hiking,
skiing) require levels of exertion that some people with chronic medical conditions may be unaccustomed
to: one paper estimated exercise during recreational diving to equal 7 metabolic equivalents of task [28]. It
is always prudent for people with bronchiectasis and advising physicians to be aware of functional
limitations. If in doubt, a formal exercise test may be performed when planning sports activities.
Where should people with bronchiectasis get help if they become unwell while travelling?
Recommendations
24) Prior to travel, people with bronchiectasis should be advised on increasing airway clearance if suffering
an exacerbation while away (96% agreement).
25) Prior to travel, people with bronchiectasis should be advised when to take antibiotics, including a
recommendation for an oral antibiotic, dose and duration (100% agreement).
26) People with bronchiectasis should be advised when and where to seek medical care at their destination
(88% agreement).
Exacerbations are periods of time when an increase in symptoms (sputum purulence and quantity,
dyspnoea, malaise, fever) occur [16, 29]. The aetiology of pulmonary exacerbations is most often presumed
to be inflammatory/infectious, although not always known, and some patients are more prone to
exacerbations than others [16]. Current guidelines recommend treating pulmonary exacerbations of
bronchiectasis with increasing airway clearance and antibiotics directed against pathogenic organisms in
sputum, usually for 10–14 days [22].
When planning travel, practical advice should be given to prepare the individual for the possibility of
experiencing a pulmonary exacerbation. In such cases, increasing the frequency of airway clearance is
recommended, and prescribing antibiotics which are active against previous pathogen(s) in sputum to be
taken in case of a pulmonary exacerbation is useful, especially for those with a history of previous
exacerbations. It is likewise recommended to plan with the person with bronchiectasis to step up treatment
in different scenarios (e.g. mild or more severe exacerbation, occurrence of haemoptysis). While
self-treatment of pulmonary exacerbations may be safe in many cases, it is always useful to know the
health facilities in the destination in case self-management fails. It likewise may not be feasible to rely on
oral antibiotics in those with very severe bronchiectasis, those with respiratory failure or people chronically
infected with highly resistant organisms, for which intravenous antibiotics are indicated in exacerbations.
Likewise, people with bronchiectasis should be educated about occurrence of haemoptysis, in which
medical care is usually required.
Discussion
People with bronchiectasis frequently travel for leisure or business. It is desirable for people with any
chronic illness to engage in activities that keep them socially active, and therefore find ways for them to
carry on their travelling plans while not compromising regular treatment. The key to keeping healthy
while travelling is planning ahead. This involves considering several key factors: those related to the
severity of bronchiectasis (presence of chronic infection, respiratory insufficiency, and frequency of
exacerbations); those related to the destination (climate, air quality, endemic microorganisms, availability
of healthcare, planned activity), and finally, those related to transportation (including mode of travel (air
or surface), time in transport and at airports, and conditions, including storage and access to electricity
during travel). Knowing these factors is necessary for “tailoring” recommendations to the patient and the
journey.
With very little evidence available on the questions raised, it was not possible to make strong
recommendations, and all recommendations are based on “expert opinion”. This document is designed to
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provide advice to patients and physicians regarding travel and should not be confused with a clinical
practice guideline. Although many statements that were considered did not reach a high level of
agreement; it should be noted that almost all of these statements may be true for certain people with
certain conditions: tailoring these recommendations is necessary when planning travel.
This document is the result of a collaboration between the bronchiectasis PAG volunteers coordinated by
the ELF, and bronchiectasis experts affiliated to the EMBARC collaboration. Questions were raised and
refined by members of the PAG, who also participated in the writing of this document. Regarding
statements that were not included as recommendations: it was commented repeatedly by the respondents
that while some of these recommendations may be considered in certain situations, applying them to the
entire population of people with bronchiectasis and all travel scenarios may result in unnecessary
limitations. It is therefore advised to consider other aspects of travelling not addressed here in advising
patients before travel.
Conclusion
Most people with bronchiectasis can safely travel for leisure or business. Planning ahead is essential to
maintaining health while enjoying available activities.
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